Payment overview · 2025
General Payments
$5,405.84
136 reported records · 22 companies
Healthcare provider profile · identity verified
Jorge Fernando Robles, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL CENTRO, CA · NPI 1366517716
Verified facts
What the public records show
CMS Open Payments records show Jorge Fernando Robles, MD received $5,405.84 in general payments during 2025 across 136 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Korlym, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 608 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 697 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Korlym by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 697 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 582 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Tymlos by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $3,020.22 | 55.9% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $338.83 | 6.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $285.46 | 5.3% | 19 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $220.12 | 4.1% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $202.22 | 3.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $180.13 | 3.3% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $169.81 | 3.1% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $163.78 | 3.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.55 | 2.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.90 | 2.0% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $89.54 | 1.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.95 | 1.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $73.13 | 1.4% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $67.45 | 1.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $66.21 | 1.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.48 | 1.1% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.07 | 0.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $24.20 | 0.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.52 | 0.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.97 | 0.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.77 | 0.3% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $13.53 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,905.84 | 132 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500.00 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $2,879.78 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $338.83 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $216.12 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $202.22 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $195.04 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $169.81 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $163.78 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.72 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.95 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $95.81 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.78 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $89.54 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.95 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $67.45 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $66.21 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.23 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 608 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 697 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 80 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 162 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 582 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
162 | 69 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
608 | 169 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
80 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
697 | 173 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 73 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
697 | 173 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
120 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
582 | 130 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
138 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
89 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 1815 | 495 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1406 | 353 |
| Amlodipine Besylate | Amlodipine Besylate | 1279 | 356 |
| Omeprazole | Omeprazole | 1206 | 369 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1153 | 380 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1145 | 351 |
| Lisinopril | Lisinopril | 1020 | 283 |
| Valsartan | Valsartan | 861 | 226 |
| Jardiance | Empagliflozin | 697 | 173 |
| Tamsulosin Hcl | Tamsulosin Hcl | 672 | 232 |
| Losartan Potassium | Losartan Potassium | 652 | 195 |
| Gabapentin | Gabapentin | 647 | 233 |
| Farxiga | Dapagliflozin Propanediol | 608 | 169 |
| Ozempic | Semaglutide | 582 | 130 |
| Metoprolol Tartrate | Metoprolol Tartrate | 556 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 497 | 167 |
| Ibuprofen | Ibuprofen | 485 | 216 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 477 | 178 |
| Furosemide | Furosemide | 424 | 149 |
| Sertraline Hcl | Sertraline Hcl | 408 | 145 |
| Lorazepam | Lorazepam | 377 | 142 |
| Simvastatin | Simvastatin | 340 | 97 |
| Azelastine Hcl | Azelastine Hcl | 336 | 172 |
| Zolpidem Tartrate | Zolpidem Tartrate | 330 | 98 |
| Alendronate Sodium | Alendronate Sodium | 308 | 103 |
| Fluticasone Propionate | Fluticasone Propionate | 280 | 142 |
| Carvedilol | Carvedilol | 277 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 68 |
| Tresiba Flextouch U-200 | Insulin Degludec | 240 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 80 |
| Chlorthalidone | Chlorthalidone | 210 | 67 |
| Eliquis | Apixaban | 206 | 73 |
| Potassium Chloride | Potassium Chloride | 206 | 75 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 203 | 64 |
| Finasteride | Finasteride | 192 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 192 | 52 |
| Tramadol Hcl | Tramadol Hcl | 173 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 170 | 51 |
| Azithromycin | Azithromycin | 162 | 143 |
| Linzess | Linaclotide | 162 | 69 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 37 |
| Vascepa | Icosapent Ethyl | 155 | 45 |
| Meloxicam | Meloxicam | 153 | 54 |
| Doxazosin Mesylate | Doxazosin Mesylate | 152 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 58 |
| Icosapent Ethyl | Icosapent Ethyl | 141 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 138 | 122 |
| Rybelsus | Semaglutide | 138 | 36 |
| Meclizine Hcl | Meclizine Hcl | 137 | 55 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 131 | 37 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 43 |
| Xarelto | Rivaroxaban | 125 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 41 |
| Entresto | Sacubitril/Valsartan | 120 | 36 |
| Allopurinol | Allopurinol | 119 | 32 |
| Tradjenta | Linagliptin | 119 | 27 |
| Januvia | Sitagliptin Phosphate | 115 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 112 | 64 |
| Celecoxib | Celecoxib | 107 | 51 |
| Prednisone | Prednisone | 105 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 30 |
| Gemtesa | Vibegron | 89 | 29 |
| Memantine Hcl | Memantine Hcl | 88 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 76 |
| Terbinafine Hcl | Terbinafine Hcl | 86 | 39 |
| Dapagliflozin | Dapagliflozin Propanediol | 85 | 57 |
| Nifedipine Er | Nifedipine | 85 | 27 |
| Nystatin | Nystatin | 84 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Trulicity | Dulaglutide | 81 | 21 |
| Kerendia | Finerenone | 80 | 30 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 80 | 45 |
| Trazodone Hcl | Trazodone Hcl | 78 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 26 |
| Famotidine | Famotidine | 74 | 28 |
| Midodrine Hcl | Midodrine Hcl | 70 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 69 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 66 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 36 |
| Alprazolam | Alprazolam | 64 | 20 |
| Levetiracetam | Levetiracetam | 64 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 14 |
| Clonazepam | Clonazepam | 63 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 60 | 55 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 59 | 50 |
| Myrbetriq | Mirabegron | 57 | 23 |
| Spironolactone | Spironolactone | 57 | 18 |
| Pregabalin | Pregabalin | 56 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 16 |
| Lactulose | Lactulose | 55 | 21 |
| Sucralfate | Sucralfate | 55 | 25 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 55 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 17 |
| Megestrol Acetate | Megestrol Acetate | 50 | 20 |
| Nitroglycerin | Nitroglycerin | 49 | 22 |
| Clonidine Hcl | Clonidine Hcl | 47 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 29 |
| Glimepiride | Glimepiride | 45 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 33 |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 40 | 18 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Tymlos | Abaloparatide | 40 | 12 |
| Dutasteride | Dutasteride | 39 | 11 |
| Bumetanide | Bumetanide | 38 | 17 |
| Metformin Hcl Er | Metformin Hcl | 38 | 11 |
| Methimazole | Methimazole | 38 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 14 |
| Fluconazole | Fluconazole | 35 | 32 |
| Novolog Flexpen | Insulin Aspart | 35 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | 12 |
| Digoxin | Digoxin | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 31 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | 15 |
| Prolia | Denosumab | 30 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 13 |
| Naproxen | Naproxen | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 13 |
| Humalog Kwikpen U-200 | Insulin Lispro | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | 12 |
| Creon | Lipase/Protease/Amylase | 26 | 13 |
| Donepezil Hcl | Donepezil Hcl | 26 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 18 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Klor-Con 8 | Potassium Chloride | 23 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Ibu | Ibuprofen | 22 | 15 |
| Constulose | Lactulose | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Hydrocortisone | Hydrocortisone | 17 | 14 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Korlym | Mifepristone | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | 11 |
| Xifaxan | Rifaximin | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,405.84 · 136 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPVAXIVE, CREON, CeQur Simplicity, FARAPULSE, FARXIGA, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, Omnipod, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, XIFAXAN, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error